NCT04942080 Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)
| NCT ID | NCT04942080 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Angers |
| Condition | Myeloproliferative Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 260 participants |
| Start Date | 2021-10-28 |
| Primary Completion | 2027-04-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 260 participants in total. It began in 2021-10-28 with a primary completion date of 2027-04-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prospective study to evaluate the relevance of CALR allele burden monitoring as a molecular marker of disease progression.
Eligibility Criteria
Inclusion Criteria: * adults (age ≥18 years), * affiliated to the national social security system, * with CALR mutated myeloproliferative neoplasm diagnosed between 2006 - 2020, * for which at least one sample is available at the time of diagnosis or before cytoreductive treatment, * who signed the consent to participate in the study, * included, or consenting to be included, in the national clinical-biological database of France Intergroupe Syndrome Myéloprolifératifs (FIM). Exclusion Criteria: * patient with another active hematological disease or cancer at the time of diagnosis, * person subject to legal protection scheme or incapable of giving consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04942080 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myeloproliferative Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04942080 currently recruiting?
Yes, NCT04942080 is actively recruiting participants. Contact the research team at Laurane.Cottin@chu-angers.fr for enrollment information.
Where is the NCT04942080 trial being conducted?
This trial is being conducted at Angers, France, Bordeaux, France, Brest, France, Cholet, France and 6 additional locations.
Who is sponsoring the NCT04942080 clinical trial?
NCT04942080 is sponsored by University Hospital, Angers. The trial plans to enroll 260 participants.